Evenity (romosozumab)

Amgen flag
Biotech

Safety scare prompts FDA to reject Amgen’s romosozumab

Officials knocked back the filing after phase 3 data linked the sclerostin-targeting antibody to an increased risk of cardiovascular adverse events.
Nick Paul Taylor Jul 17, 2017 4:15am
Bones

Shock for Amgen, UCB as side effects undermine romo trial

May 22, 2017 8:57am
Bones

Radius osteoporosis drug bests placebo in PhIII; eyes 2017 FDA approval

Aug 17, 2016 9:58am